- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acquired thrombotic thrombocytopenic purpura
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 1712KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 453KB)
Caplacizumab – July 2020
Caplacizumab: Injection set containing 1 vial powder for injection 10 mg and 1 pre-filled syringe solvent 1 mL; Cablivi®
Last updated
13 November 2020